Custom Needle Preparation for Suprachoroidal Steroid Injection (One Year Results)

One Year Results for Suprachoroidal Triamcinolone Acetonide Injection in Various Retinal Diseases

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05496530

Enrollment

100

Registered

2022-08-11

Start date

2022-07-10

Completion date

2023-08-15

Last updated

2022-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Macular Edema, Retinal Vein Occlusion, Vogt Koyanagi Harada Disease

Brief summary

Suprachoroidal drug delivery is a recent route for managing various ocular conditions. Safety and long term results are still under investigations.

Detailed description

In this study, we aim to analyze the long term results of suprachoroidal injection in treating various retinal diseases to focus on its efficacy, safety and long term ocular effects as ocular hypertension, cataract progression and macular edema resolution.

Interventions

DRUGSuprachoroidal triamcinolone acetonide injection

Pars plana suprachoroidal injection of 4mg//0.1ml triamcinolone acetonide.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to 80 Years

Healthy volunteers

Inclusion criteria

* cases with central macular thickness more than 250 microns measured by optical coherence tomography due to one of the following conditions: * Diabetic macular edema * Vogt-koyanagi Harada disease * Retinal vein occlusion.

Exclusion criteria

* other causes of increased macular thickness as age related macular degeneration and myopic choroidal new vascularization. * Cases with confirmed diagnosis of glaucoma.

Design outcomes

Primary

Measure	Time frame	Description
Visual acuity	Baseline and up to one year after injection.	Changes noted in vision after injection measured 8n logMar units by snellen chart.

Secondary

Measure	Time frame	Description
Central macular thickness	Baseline and up to one year after injection.	Changes noted in central macular thickness after injection measured by optical coherence tomography in microns.

Other

Measure	Time frame	Description
Intraocular pressure	Baseline and up to one year after injection.	Changes noted in intraocular pressure after injection measured by applanation tonometry in millimeter mercury.

Countries

Egypt

Contacts

Primary ContactAhmed A Tabl

ahmad4lg@gmail.com01222328766

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026